CKD 712

Drug Profile

CKD 712

Alternative Names: CKD-712

Latest Information Update: 20 Sep 2010

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Chong Kun Dang
  • Class Alkaloids; Isoquinolines
  • Mechanism of Action I-kappa B kinase inhibitors; NF-kappa B inhibitors; Nitric oxide synthase type II inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Sepsis

Most Recent Events

  • 13 May 2010 Phase I development is ongoing in South Korea
  • 03 May 2010 CKD 712 is available for licensing worldwide (http://210.92.140.4/research.htm)
  • 10 Sep 2007 Preclinical trials in Sepsis in South Korea (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top